Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Advanced Pharma > Bone/Joint Disorders - textbook > Flashcards

Bone/Joint Disorders - textbook Flashcards

1
Q

osteoporosis

A

common & often silent disorder causing significant morbidity and mortality and reduced quality of lif

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

osteoporosis: characterized by

A

low bone density
loss of bone strength resulting in an inc risk & rate of bone fx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

risk of developing osteoporosis

A

-age (inc after 50)
-sex (African Americans have the highest BMD, while Asian Americans have the lowest)
-race/ethnicity (white, old women have the highest %)
-common sites of fx: spine (kyphosis), hip, wrist but all can be affected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

moat common skeletasl disorder

A

osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

osteoporosis classified as

A

primary (no known cause) - most often: postmenopausal women & aging men
secondary (caused by drugs or other diseases)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

why do postmenopausal women have accelerated bone loss?

A

loss of estrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

secondary causes of osteoporosis

A

such as hypogonadism, are found more commonly in men with low trauma fractures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

osteoporosis is known for

A

an imbalance in bone remodeling (accelerated w/ decreased estrogen in the first 5 years)

osteoclastic activity is enhanced, resulting in overall bone loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BMD

A

low bone mineral density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

diagnosis osteoporosis

A

-assessment of BMD
-vertebral imagining
-labs
-other factors for secondary causes
-biochemical markers for bone turnover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

measuring BMD

A

dual-energy x-ray absorptiometry (DXA) (WHO recommended) to measure central (hip and/or spine) and peripheral (heel, forearm, or hand) sites: peripheral quantitative computed tomography, radiographic absorptiometry, single-energy x-ray absorptiometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

T-scores & Z-scores: indicating osteoporosis

A

T-score more than –2.5 standard deviations below the mean BMD in young adults

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

osteopenia

A

low bone mass, is defined as a T-score between –2.5 and –1.0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

National Osteoporosis Foundation (NOF) and AACE recommend BMD measurements in the following groups

A

women age 65 and older, men age 70 and older, perimenopausal women and men age 50 to 69 with risk factors, anyone with a fracture after age 50, and adults with a secondary cause for osteoporosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

vertebral imagining is recommended in patients with a central T-score:

A

–1.0 or less and at least one other factor:
(a) women age 70 and older and men age 80 and older
(b) reported decrease in height of 4 or more centimeters
(c) reported or documented prior vertebral fracture
(d) glucocorticoid therapy of at least 5 mg daily of prednisone (or equivalent) for at least 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

screening labs:

A

-complete blood count cell
-serum chemistries (electrolytes w/ calcium, phosphorus, liver enzymes)
- vit D
-urinalysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

monitoring bone turnover markets (BTMs)

A

c-terminal telopeptide (CTX) for bone resorption
serum carboxy-terminal propeptide of type I collagen (PINP) for bone formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

nonmodifiable risk factors

A

-family hx
-age
-ethnicity
-sex
-concomitant disease states
-smoking
-low calcium intake
-poor nutrition
-inactivity
-heavy alcohol use
-vit D deficiency

prevention should start at an early age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

calcium supplement doses should be limited to

A

500-600mg per dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

calcium carbonate

A

take w/ food to maximize absorption
-pts taking PPI/h2RAs difficulty absorbing due to reduced stomach acidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

calcium citrate

A

do not need an acid environment for absorption
-taken w/ or w/o food

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

calcium supplements a/e

A

-constipation
-bloating
-cramps
-flatulence (esp calcium carbonate)

23
Q

calcium salts reduce absorption of

A

iron and some antibiotics, such as tetracycline and fluoroquinolones

**admin calcium supplements 2 hrs prior or 4 hrs after **

24
Q

NOF recommends a daily vitamin D intake of

A

800 - 1000 IU for all adults age 50+

max for chronic use is 4000 IU/day

25
Q

bisphoshonates

A

1st-line option for M & F in preventing osteporotic fractures
-decrease resorption by quickly binding to the bone matrix and inhibiting osteoclastic activity

26
Q

highest affinity to bone from bisphosphonates class are:

A

alendronate and zoledronic acid (IV)

27
Q

“broad spectrum” due to efficacy in decreasing hip, vertebral and nonvertebral fractures

A

alendronate, risedronate, and zoledronic acid

28
Q

which bisphosphonate is for postmenopausal osteoporosis

A

ibandronate

29
Q

a/e of bisphosphonate

A

-bone, muscle, joint pain (stop when dicon’t)
-upper GI (N/V/D), dyspepsia, abd pain, GERD
-esophageal ulceration, erosion w/ bleeding, perforation, stricture, esophagitis (inc w/ age, previous upper GI tract disease, use of NSAID) …risk decreased w/ once-week admin

30
Q

zoledronic acid

A

monitor creatinine, alkaline phosphatase, phosphate, magnesium, and calcium prior to each dose
-flu-like symptoms last for days (give Tylenol)

31
Q

long-term use of bisphosphonate

A

-osteonecrosis of the jaw (ONJ)
-atypical femoral fractures (AFF)

discontinue after 10 years of oral therapy or 6 years of IV therapy

32
Q

oral bishosphonates absorption

A

is poor especially when taken with food or calcium supplementation

33
Q

Contraindications to bisphosphonates

A

hypersensitivity, hypocalcemia, pregnancy, and renal impairment (creatinine clearance less than 30–35 mL/min [0.50–0.58 mL/s]), or failure

-esophageal abnormalities delaying swallowing (eg, achalasia, stricture), GI malabsorption (eg, celiac disease, Crohn disease, or gastric bypass), or who cannot remain upright for 30 minutes should avoid oral bisphosphonates; consider IV bisphosphonates for these patients

34
Q

denosumab

A

a broad-spectrum, twice-yearly injectable human monoclonal antibody that prevents nuclear factor-kappa B ligand (RANKL) from binding to its receptor, thereby decreasing osteoclast maturity, function, and survival

use up to 10 years
injected once q6months

35
Q

denosumab: proven for

A

benefit in reducing hip, vertebral, and nonvertebral fractures through its antiresorptive effects

-its reversible; decreases in BMD may be seen within months of discontinuation of therapy

-drug holidays not recommended bc ^^^

36
Q

patient cant tolerate bisphosphonate, rx

A

denosumab

37
Q

denosumab a/e

A

back pain, arthralgias, fatigue, headache, dermatologic reactions, D/N

serious a/e: hypophosphatemia, hypocalcemia, dyspnea, and skin and other infections

38
Q

parathyroid hormone analogs

A

-teriparatide (recombinant human PTH [1-34]
-abalopratatide (synthetic analog of PTH-related protein [PTHrP] for postmenopausal only

activation of receptor promotes osteoblastic activity and bone formation but also enhances bone resorption

(not for hip fracture reduction)

1st line therapy for prior fractures or those deemed very high risk
-daily subq self-injection prefilled pens

39
Q

parathyroid hormone analogs: a/e

A
  • N
  • headache
  • leg cramps
    -dizziness
    -orthostatic hypotension
  • hypercalciuria
  • hypercalcemia

abaloparatide=palpitations

40
Q

parathyroid hormone analogs: contraindicated in

A

hypercalcemia, hyperparathyroidism, patients at risk of osteosarcoma (Paget’s disease, hx of skeletal radiation)

** Black box warning: observation of osteosarcoma in animal studies, not confirmed in humans **

therapy for 2 years & s/n discon’t

41
Q

Romosozumab

A

monoclonal antibody that promotes bone formation and reduces resorption by binding to and inhibiting sclerostin, thereby increasing production of mature osteoblasts
higher reduction in vertebral fx than alendronate and denosumab

indicated for treatment of osteoporosis in postmenopausal women at high risk of fracture (history of fracture or multiple risk factors for fracture) who have failed or are intolerant to other treatment options

42
Q

administration of romosozumab

A

210 mg is administered as 2 subq injections once monthly by a healthcare provider

-treatment recommended for 12 months
-start on bisophosphonate or denosumab to prevent the loss of benefit, including gains in BMD and reduction in fracture risk

43
Q

black box warning for romosozumab

A

risk of myocardial infarction, stroke, or cardiovascular death.38 Patients should not take the drug if they have had a stroke or myocardial infarction in the past yea

44
Q

raloxifine

A

estrogen-like activity on bones and cholesterol metabolism and estrogen antagonist activity in breast and endometrium
-reduces bone resorption and decreases overall bone turnover
-not effective in reduction hip or nonvertebral fractures
-decreases breast cancer risk in pts at risk for osteoporosis

45
Q

raloxifine: a/e

A

hot flushes, leg cramps, and increased risk of venous thromboembolism

* previous hx of VTE is a contraindication for this therapy*

46
Q

calcitonin

A

naturally occurring mammalian hormone that plays a major role in regulating calcium levels
-inhibits bone resorption by binding to osteoclast receptors

47
Q

calcitonin: a/e

A

-rhinitis
-nasal irritation
-dryness

-safety & effectiveness of calcitonin has been studied for up to 5 years. Once discontinued, benefits of drug therapy are lost within 1 to 2 years

48
Q

estrogen

A

either alone or in combination with a progestin as hormone replacement therapy (HRT), has a long history as an effective treatment for osteoporosis

-may be considered in women with past hysterectomy intolerant to other therapies who are less than 10 years postmenopause and experiencing vasomotor symptoms

49
Q

estrogen

A

either alone or in combination with a progestin as hormone replacement therapy (HRT), has a long history as an effective treatment for osteoporosis

-may be considered in women with past hysterectomy intolerant to other therapies who are less than 10 years postmenopause and experiencing vasomotor symptoms

50
Q

combination therapy

A

The AACE states that addition of a bisphosphonate or denosumab to prevent hip fracture may be reasonable in patients using raloxifene to reduce breast cancer risk

51
Q

Glucocorticoids

A

eg, prednisone, hydrocortisone, methylprednisolone, and dexamethasone) play a significant role in bone remodeling, including increasing bone resorption, inhibiting bone formation, and changing bone quality

52
Q

he American College of Rheumatology (ACR) recommends oral bisphosphonate therapy for all patients …

A

age 40 or over at moderate to high risk of fracture (as determined by FRAX) receiving glucocorticoids (prednisone 2.5 mg or more daily or equivalent) for 3 months or longer

53
Q

for patients unable to take oral bisphosphonates

A

lternative therapy recommendations include IV bisphosphonates, teriparatide, denosumab, and raloxifene in that order.46 Frequent clinical fracture risk assessment with BMD testing every 1 to 3 years is recommended while receiving glucocorticoids

Advanced Pharma (27 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions